Frontiers in Molecular Biosciences (Feb 2023)

Role of LGMN in tumor development and its progression and connection with the tumor microenvironment

  • Safir Ullah Khan,
  • Safir Ullah Khan,
  • Ibrar Muhammad Khan,
  • Munir Ullah Khan,
  • Muhammad Azhar Ud Din,
  • Muhammad Zahoor Khan,
  • Nazir Muhammad Khan,
  • Yong Liu

DOI
https://doi.org/10.3389/fmolb.2023.1121964
Journal volume & issue
Vol. 10

Abstract

Read online

Legumain (LGMN) has been demonstrated to be overexpressed not just in breast, prostatic, and liver tumor cells, but also in the macrophages that compose the tumor microenvironment. This supports the idea that LGMN is a pivotal protein in regulating tumor development, invasion, and dissemination. Targeting LGMN with siRNA or chemotherapeutic medicines and peptides can suppress cancer cell proliferation in culture and reduce tumor growth in vivo. Furthermore, legumain can be used as a marker for cancer detection and targeting due to its expression being significantly lower in normal cells compared to tumors or tumor-associated macrophages (TAMs). Tumor formation is influenced by aberrant expression of proteins and alterations in cellular architecture, but the tumor microenvironment is a crucial deciding factor. Legumain (LGMN) is an in vivo-active cysteine protease that catalyzes the degradation of numerous proteins. Its precise biological mechanism encompasses a number of routes, including effects on tumor-associated macrophage and neovascular endothelium in the tumor microenvironment. The purpose of this work is to establish a rationale for thoroughly investigating the function of LGMN in the tumor microenvironment and discovering novel tumor early diagnosis markers and therapeutic targets by reviewing the function of LGMN in tumor genesis and progression and its relationship with tumor milieu.

Keywords